| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2026―Mar―02 |
Fluoxetine inhibits severe acute respiratory syndrome coronavirus 2 replication in vitro |
Yethindra Vityala, Tugolbai Tagaev, Elmira Mainazarova, Ziiabidin Aidarov, Middela Karthik |
| 2 |
[GO] |
2026―Mar―02 |
Efficacy and safety of remdesivir for patients with severe acute respiratory syndrome coronavirus 2 infection: A systematic review of randomized controlled trials |
Jitendra Meena, Amit Agarwal, Amit Sandhu, Pranita Pradhan, Meenu Singh |
| 3 |
[GO] |
2026―Mar―02 |
Effects of Traditional Chinese Medicine on Restoroing the immune balance of mild-to-moderate Patients with new coronavirus |
Sijie Chen, Hongmei Li, Zihan Jiang, Jingtian Liang, Ao Zhou |
| 4 |
[GO] |
2026―Mar―02 |
Clozapine, pneumonia, and COVID-19 |
Pathum Sookaromdee, Viroj Wiwanitkit |
| 5 |
[GO] |
2026―Jan―07 |
Cost-effectiveness analysis of intradermal versus classical intramuscular COVID-19 vaccine administration: Specific concern on update situation due to emerging Omicron variant |
Pathum Sookaromdee, Viroj Wiwanitkit |
| 6 |
[GO] |
2025―Aug―22 |
In silico drug repurposing targeting fusion and nucleoprotein of human metapneumovirus: A step toward pandemic preparedness |
Harshita Rajput, Gajendra Choudhary, Hadiya Siddiqui, Anushka Ghosh, Manisha Prajapat, Ajay Prakash, Bikash Medhi |
| 7 |
[GO] |
2025―Jul―21 |
Comparison of renal function of the patients receiving linagliptin or vildagliptin in uncontrolled type 2 diabetes mellitus: An observational study in the backdrop of the COVID-19 pandemic |
Sailayee Chaudhuri, Supreeti Biswas, Sandip Mukhopadhyay, Somnath Dasgupta |
| 8 |
[GO] |
2025―Jul―09 |
Re-emergence of COVID-19 and preparedness |
Gajendra Choudhary, Harshita Rajput, Bikash Medhi |
| 9 |
[GO] |
2024―Sep―09 |
Correlation between essential metals and severe acute respiratory syndrome coronavirus 2 infection |
Anoop Kumar, Manisha Thakur, Mohini Chaurasia, S. J. S. Flora |
| 10 |
[GO] |
2024―May―23 |
Sharing experience: Hydroxychloroquine in preexposure prophylaxis against COVID-19 |
Chanda Kulkarni, Adil Sadiq, Arya Gigi, Ambili Devassia, Georgeena George |
| 11 |
[GO] |
2024―May―23 |
Potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe COVID-19 |
Yethindra Vityala, Tugolbai Tagaev, Sagynali Mamatov, Ziiabidin Aidarov, Panchadcharam Harinath |
| 12 |
[GO] |
2024―May―23 |
COVID-19 associated mucormycosis, host-iron assimilation: Probiotics can be a novel therapy |
Ankit Bhardwaj, Vandana Roy |
| 13 |
[GO] |
2024―May―23 |
Long coronavirus disease: Consequences of COVID-19 infection and vaccine on cardiovascular diseases |
ShobanBabu Varthya, Krishna Tiwari, Aswini Saravanan, Abhishek Anil, Surjit Singh |
| 14 |
[GO] |
2024―May―23 |
Antimicrobial resistance: An unseen threat prowling behind the COVID-19 outbreak |
Bikash Medhi, Vidya Mahalmani, J Kumaravel, Manav Jain, Ajay Prakash |
| 15 |
[GO] |
2024―May―23 |
Pattern of clinical research in the era of COVID-19 pandemic: A new learning experience for the present as well as future |
Bikash Medhi, VidyaM Mahalmani, Ankita Semwal, Harpinder Kaur, Sukhmeet Kaur, Ajay Prakash |
| 16 |
[GO] |
2024―May―23 |
Successful management of delayed hyaluronidase hypersensitivity after subtenon's anesthesia during the COVID-19 pandemic: A rare case report |
Bharat Gurnani, Kirandeep Kaur |
| 17 |
[GO] |
2024―May―23 |
Drug development process and COVID-19 pandemic: Flourishing era of outsourcing |
KH Reeta, Himika Wasan, Devendra Singh, Pooja Gupta, YogendraKumar Gupta |
| 18 |
[GO] |
2024―May―23 |
Adverse drug reactions of itolizumab in COVID-19 patient: A case report |
ManojP Dandekar, Ziauddin Mohammed, Kandi Suryachandra |
| 19 |
[GO] |
2024―May―23 |
Rhino-orbital-cerebral mucormycosis in COVID-19 patients - Taming the black evil with pharmacological weapons |
Bharat Gurnani, Kirandeep Kaur |
| 20 |
[GO] |
2024―May―23 |
Efficacy and safety of inhaled nitric oxide in the treatment of severe/critical COVID-19 patients: A systematic review |
Bikash Medhi, Ajay Prakash, Sukhmeet Kaur, Charanjeet Kaur, PraisyK Prabha, Anusuya Bhatacharya, Phulen Sarma |
| 21 |
[GO] |
2024―May―23 |
Intradermal versus intramuscular COVID-19 vaccination aiming at protection for delta variant: cost utility analysis |
Rujittika Mungmunpuntipantip, Viroj Wiwanitkit |
| 22 |
[GO] |
2024―May―23 |
Attitude toward COVID-19 vaccination: A cross-sectional study on healthcare professionals |
Ramachandran Balaraman, Suresh Velumani, Patel Arpita |
| 23 |
[GO] |
2024―May―23 |
The narrow road to a COVID-19 vaccine |
BimalKumar Das, SheshPrakash Maurya, Namrata Das, Hitender Gautam, Ravinder Singh |
| 24 |
[GO] |
2024―May―23 |
Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors |
Erkan Cure, Adem Kucuk, MedineCumhur Cure |
| 25 |
[GO] |
2024―May―23 |
Desensitization to liposomal amphotericin B after anaphylaxis in a patient with COVID-19-associated mucormycosis - A case with review of literature |
Animesh Ray, Satish Swain, Naveet Wig, Anjan Trikha |
| 26 |
[GO] |
2024―May―23 |
Peptides and peptidomimetics as a therapeutic candidate for the treatment of COVID-19: A brief review |
Bikash Medhi, J Kumaravel, Harvinder Singh, Sukhmeet Kaur, Ajay Prakash |
| 27 |
[GO] |
2024―May―23 |
Rhino-orbital-cerebral-mucormycosis in COVID-19: A systematic review |
Bikash Medhi, Anusuya Bhattacharyya, Phulen Sarma, DibyaJyoti Sharma, KarunaKumar Das, Hardeep Kaur, Manisha Prajapat, Subodh Kumar, Seema Bansal, Ajay Prakash, Pramod Avti, Prasad Thota, DibbantiHarikrishna Reddy, BhaswatiSharma Gautam |
| 28 |
[GO] |
2024―May―23 |
Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis |
Bikash Medhi, Anusuya Bhattacharyya, Subodh Kumar, Phulen Sarma, Hardeep Kaur, Manisha Prajapat, Nishant Shekhar, Seema Bansal, Pramod Avti, Mythili Hazarika, Saurabh Sharma, Dhruv Mahendru, Ajay Prakash |
| 29 |
[GO] |
2024―May―23 |
Role of Vitamin D in COVID-19: Correspondence |
Pathum Sookaromdee, Viroj Wiwanitkit |
| 30 |
[GO] |
2024―May―23 |
Decreased mortality among hospitalized coronavirus disease 2019 patients who underwent anticoagulant therapy with heparin |
Vityala Yethindra, Tugolbai Tagaev |
| 31 |
[GO] |
2024―May―23 |
In search for a panacea for coronavirus disease-19: Analysis of ongoing clinical trials for the management of coronavirus disease-19 pandemic in India |
Vandana Roy, Nidhi Maheshwari |
| 32 |
[GO] |
2024―May―23 |
Virtual screening and molecular dynamics simulation study of approved drugs as a binder to the linoleic acid binding site on spike protein of SARS-CoV-2 and double mutant (E484Q and L452R) |
Bikash Medhi, Manisha Prajapat, Phulen Sarma, Nishant Shekhar, Arushi Chauhan, Gurjeet Kaur, Anusuya Bhattacharyya, Pramod Avti, Gajendra Choudhary, Seema Bansal, Saurabh Sharma, Hardeep Kaur, Subodh Kumar, Harvinder Mann, Anupam Raja, Ashutosh Singh, Rahul Singh, AmitRaj Sharma, Ajay Prakash |
| 33 |
[GO] |
2024―May―23 |
Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era |
Bikash Medhi, Niraj Niraj, SoniaShinde Mahajan, Ajay Prakash, Phulen Sarma |
| 34 |
[GO] |
2024―Apr―30 |
Neutralization antibody titer and change in 50% protection after the third dose of the COVID-19 vaccine |
Rujittika Mungmunpuntipantip, Viroj Wiwanitkit |
| 35 |
[GO] |
2024―Mar―08 |
Expected usefulness of the third dose of COVID-19 vaccine for adolescents living with underlying HIV infection |
Sora Yasri, Viroj Wiwanitkit |
| 36 |
[GO] |
2024―Mar―08 |
Reduction of COVID-19 vaccine-induced neutralizing antibody and changing of molecular epidemiology pattern of omicron SARS-CoV-2 subvariant: Observed interrelationship |
Beuy Joob, Pathum Sookaromdee, Viroj Wiwanitkit |
| 37 |
[GO] |
2023―Aug―07 |
Concurrent administration of COVID-19 vaccine and seasonal influenza vaccine: No increased estimated vaccine-related mortality rate |
Pathum Sookaromdee, Viroj Wiwanitkit |
| 38 |
[GO] |
2023―Aug―07 |
Kratom (Mitragyna speciosa) and COVID-19: How about the current evidence? |
Amnuay Kleebayoon, Viroj Wiwanitkit |
| 39 |
[GO] |
2022―Mar―29 |
Aging, VO2 max, entropy, and COVID-19 |
Michael Spedding, Robin Marvaud, Adrien Marck, Quentin Delarochelambert, JeanFrancois Toussaint |
| 40 |
[GO] |
2022―Mar―29 |
An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies |
Suparna Chatterjee, Shouvik Choudhury, Debaleena Das |
| 41 |
[GO] |
2021―Dec―30 |
Chemoprophylaxis against COVID-19 among health-care workers using Ivermectin in low- and middle-income countries: A systematic review and meta-analysis |
TaoreedAdegoke Azeez, Sulaiman Lakoh, AdedapoAdegboyega Adeleke, OluwanifemiTolulase Balogun, BabatundeJohn Olanipekun, FiyinfoluwaIbukun Olusola |
| 42 |
[GO] |
2021―Dec―30 |
COVID-19-associated rhino-orbital-cerebral mucormycosis: A systematic review, meta-analysis, and meta-regression analysis |
Bikash Medhi, Anusuya Bhattacharyya, Phulen Sarma, Hardeep Kaur, Subodh Kumar, Jaimini Bhattacharyya, Manisha Prajapat, Ajay Prakash, Saurabh Sharma, DibbantiHarikrishna Reddy, Prasad Thota, Seema Bansal, BhaswatiSharma Gautam |
| 43 |
[GO] |
2021―Dec―30 |
Heparin-induced hyponatremia in COVID-19: A latent culprit! |
Pooja Singh, Rajesh Panda, Saiteja Kodamanchili, Abhijeet Anand |
| 44 |
[GO] |
2021―May―26 |
Modified drug regimen for ophthalmic anesthesia during COVID-19 pandemic: Revisiting pharmacological concepts |
Bharat Gurnani, Kirandeep Kaur |
| 45 |
[GO] |
2021―Apr―28 |
Indian contribution toward biomedical research and development in COVID-19: A systematic review |
Bikash Medhi, Hardeep Kaur, Manpreet Kaur, Anusuya Bhattacharyya, Manisha Prajapat, Prasad Thota, Phulen Sarma, Subodh Kumar, Gurjeet Kaur, Saurabh Sharma, Ajay Prakash, PK Saifuddin |
| 46 |
[GO] |
2021―Apr―28 |
Implication of nanotechnology-based approaches to combat SARS-CoV-2 infection |
Mohsen Salmanpour, Mana Heidari, Ali-Mohammad Tamaddon |
| 47 |
[GO] |
2021―Feb―18 |
Convergence of divergent approaches to control COVID-19 |
RameshR Bhonde, Shivani Desai, ShivaniR Sainani, KetkiR Rode |
| 48 |
[GO] |
2021―Feb―18 |
Regulatory approval for COVID-19 across the globe |
Bikash Medhi, Vidya Mahalmani, T Pugazhenthan, Niti Mittal, ShobanBabu Varthya |
| 49 |
[GO] |
2021―Feb―18 |
Efficacy and safety of steroid therapy in COVID-19: A rapid systematic review and Meta-analysis |
Bikash Medhi, Phulen Sarma, Anusuya Bhattacharyya, Hardeep Kaur, Manisha Prajapat, Ajay Prakash, Subodh Kumar, Seema Bansal, Richard Kirubakaran, DibbantiHarikrishna Reddy, Gaurav Muktesh, Karanvir Kaushal, Saurabh Sharma, Nishant Shekhar, Pramod Avti, Prasad Thota |
| 50 |
[GO] |
2021―Feb―18 |
Antiviral effect of amiodarone and its possible role in COVID-19: An appraisal |
ChandraKr Das, Snehal Lonare, Mythili Hazarika |
| 51 |
[GO] |
2020―Dec―05 |
Novel therapeutic approaches toward Hantaan virus and its clinical features’ similarity with COVID-19 |
Bikash Medhi, Harvinder Singh, Harpinder Kaur |
| 52 |
[GO] |
2020―Dec―05 |
Changing drug regimen during COVID-19 pandemic lockdown: An experience from a Tertiary Eye Care Hospital as a cornea specialist |
Bharat Gurnani, Kirandeep Kaur |
| 53 |
[GO] |
2020―Dec―05 |
Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients |
Bikash Medhi, Ajay Prakash, Harvinder Singh, Hardeep Kaur, Ankita Semwal, Phulen Sarma, Anusuya Bhattacharyya, DebaPrasad Dhibar |
| 54 |
[GO] |
2020―Dec―05 |
Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times? |
Francesco Ferrara, RaffaeleLa Porta, Priscilla Santilli, Vilma D'Aiuto, Antonio Vitiello |
| 55 |
[GO] |
2020―Aug―04 |
Indian perspective of remdesivir: A promising COVID-19 drug |
YogendraKumar Gupta, Devendra Singh, Himika Wasan, Apoorva Mathur |
| 56 |
[GO] |
2020―Aug―04 |
Sofosbuvir for COVID-19 infection: A potential candidate |
Rohit Gupta, Puneet Dhamija |
| 57 |
[GO] |
2020―Aug―04 |
Psychiatric implications of the use of hydroxychloroquine in COVID-19 patients |
Sandeep Grover, Seema Rani, Aseem Mehra, Swapnajeet Sahoo |
| 58 |
[GO] |
2020―Jun―02 |
COVID-19 pandemic: A review based on current evidence |
Bikash Medhi, VidyaM Mahalmani, Dhruv Mahendru, Ankita Semwal, Sukhmeet Kaur, Harpinder Kaur, Phulen Sarma, Ajay Prakash |
| 59 |
[GO] |
2020―Jun―02 |
Coronavirus Disease-2019 Pandemic: Hopes Ride High on Targeting Known Drugs against Unkown |
Bikash Medhi, VidyaM Mahalmani, Dhruv Mahendru, Phulen Sarma, Ajay Prakash |
| 60 |
[GO] |
2020―Mar―09 |
Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach |
Bikash Medhi, Phulen Sarma, Manisha Prajapat, Pramod Avti, Hardeep Kaur, Subodh Kumar |
